Recruiting PHASE3 INTERVENTIONAL 2-arm
NCT06804590
A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis
A Randomized, Double-blind, Parallel-group, Phase III Study to Compare the Clinical Efficacy, Safety, and Immunogenicity of Denosumab Injection 9MW0311 With Prolia® in Postmenopausal Women With Osteoporosis
Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
Conditions
Postmenopausal Women Osteoporosis
Updated 1 time since 2025 Last updated: Jan 27, 2025 Started: Nov 16, 2024 Primary completion: Apr 30, 2026 Completion: Jul 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT06804590, this PHASE3 trial focuses on Postmenopausal Women Osteoporosis and remains actively recruiting participants. Sponsored by Mabwell (Shanghai) Bioscience Co., Ltd., it has been updated 1 time since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
1 version recorded Recruiting — PHASE3
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Mabwell (Shanghai) Bioscience Co., Ltd.
Data source: Mabwell (Shanghai) Bioscience Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .